Newsletter | April 15, 2025

04.15.25 -- From BPI West: Key Challenges And Benefits Of Continuous Manufacturing

SPONSOR

The debate rages on. While the automation that enables continuous processing gets a lot of hype, there are plenty of dyed-in-the-wool biopharma pros who contend that process optimization and intensification yield comparable benefits, without requiring the capital-intensive process overhaul that continuous demands. Join Bioprocess Online Live for a virtual deep dive into the scalability, sustainability, and capital implications of the continuous-versus-optimized debate. Registration is free thanks to the support of Cytiva.

FOCUS ON OUTSOURCING

From BPI West: Key Challenges And Benefits Of Continuous Manufacturing

Continuous manufacturing was a hot topic of conversation at this year's BPI West. AstraZeneca's Ken Lee, Ph.D., weighs in during an exclusive interview with Bioprocess Online.

6 Ways Single-Use Technology Will Actually Save Time And Money

Utilize these strategies to develop a functional equivalence model for single-use manufacturing equipment and assemblies for use in drug product manufacturing.

Essential Considerations For Selecting The Right Biologic Fill/Finish Partner

Partnering with a provider that prioritizes quality and yield optimization not only ensures product safety but also helps reduce operational costs.

Development, Manufacturing Of Vaccines Containing Aluminum Adjuvants

Incorporating adjuvants like aluminum salts into vaccines offers several benefits, but it's crucial to understand the challenges in developing and manufacturing these formulations to ensure a successful partnership with a CDMO.

Advancing Immune Cell Therapies And Overcoming Cost Challenges

Immune cell therapies have incredible potential for cancer treatment, and making them more cost effective is a critical consideration for improving patient access and outcomes.

The Role Of Training Devices And Education In Self-Injection Therapies

Review the evolution of injection devices and prefilled syringes, the benefits of training devices combined with patient education, and an empirical look at patient training.

Cell Based Potency Assays: De-Risk Your Path With An Experienced CDMO

Thorough characterization is key to unlocking the potential of antibody-based therapeutics. Leveraging a CDMO's extensive capabilities and expertise can allow you to navigate the biopharmaceutical development landscape.

Reducing Risk For Commercial Manufacturing Of Cell And Gene Therapies

For any biotherapeutic in development today, a critical element in achieving commercialization is reducing manufacturing risk.

OUTSOURCING SOLUTIONS

Capacity Update January 2025: Large Molecule Development - Catalent

Gene Therapy, Viral Vaccines CDMO Services - FUJIFILM Diosynth Biotechnologies

Advancing Innovative Plasmid DNA Manufacturing Solutions For CGT - Aldevron

Developing A mAb For A Small Biotech Developing Precision Medicines - Lonza

Connect With Bioprocess Online: